Revolution Medicines stock rallies on impressive daraxonrasib Phase 3 results. Here’s why RVMD shares may sustain the ...
Mo-Rez achieved confirmed objective response rates of 62% in patients with platinum-resistant ovarian cancer. Credit: MMD ...
It's almost a new lunar phase.
The biggest stories of the day delivered to your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results